Inhibition of ROS1 activity with lorlatinib reversibly suppresses fertility in male mice
Inhibition of ROS1 with lorlatinib suppressed sperm maturation and male fertility reversibly. Future exploration of molecules that specifically target ROS1 and the ROS1 pathway in the epididymis may lead to the development of safe and reversible male contraceptives.
Authors
- Ryohei Katayama
- Yuki Oyama (ORCID: https://orcid.org/0000-0003-4579-5487)
- Martin Matthew Matzuk (ORCID: https://orcid.org/0000-0002-1445-8632)
- Seiya Oura (ORCID: https://orcid.org/0000-0002-7606-732X)
- Chihiro Emori (ORCID: https://orcid.org/0000-0001-8040-2517)
- Maki Kamoshita (ORCID: https://orcid.org/0009-0009-7853-5164)
- Haruhiko Miyata (ORCID: https://orcid.org/0000-0003-4758-5803)
- Rie Iida‐Norita (ORCID: https://orcid.org/0000-0003-0104-1974)
- Masahito Ikawa (ORCID: https://orcid.org/0000-0001-9859-6217)
- Kentaro Shimada (ORCID: https://orcid.org/0009-0002-0830-9478)
Institutions
- Baylor College of Medicine (US)
- Japanese Foundation For Cancer Research (JP)
- The University of Tokyo (JP)
- The University of Texas Southwestern Medical Center (US)
- The University of Osaka (JP)
Publication Details
- Journal
- Andrology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1111/andr.13808
- Citations
- 1
- Primary Topic
- Sperm and Testicular Function
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Bill and Melinda Gates Foundation
- Takeda Science Foundation
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science
- National Institute of Child Health and Human Development
- Eunice Kennedy Shriver National Institute of Child Health and Human Development